Thomas Hogan joined the Bernt Lab as a research technician in July of 2025 after graduating from Villanova University where he studied the biotin biosynthesis pathway and the role of biotin transporter VHT1 and its transcriptional regulator VHR1. He started his time working on the COG AALL2321 Clinical Trial BH3 Profiling analysis of infant ALL immune cells in conjunction with BCL-2 Inhibitor, Venetoclax, treatment prior to T-Cell engager Blinatumomab. When not in lab Thomas enjoys golphing.